Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

GHK-Cu is discussed for hair loss treatment, with some users reporting positive results using a 4% topical serum, but concerns exist about the long-term safety of oral or injectable forms. The original poster also uses finasteride and plans to start dutasteride.

Using topical GHK-Cu 4% has reduced hair shedding, increased hair shaft diameter, and improved scalp health, but no new hair growth was observed. The user continues to use 10% Minoxidil and 1mg oral Finasteride alongside GHK-Cu.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

A user is curious why their DHT levels are not higher despite using 400mg of testosterone without finasteride, and wonders if zinc or GHK-Cu injections could be influencing this. Another user suggests that more testosterone typically leads to more DHT, but the user might be fortunate not to exceed normal DHT levels.

A 30-year-old male has been on finasteride/dutasteride for 3 years, with stable but still receding hairline, and blood tests showing high total testosterone but normal DHT and free testosterone levels. Despite challenges in gaining muscle, he maintains a good physique with a consistent lifting routine and recently improved results with creatine.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.

Dutasteride might be better for hairline due to varying levels of 5AR activity in scalps. Genetic tests can determine if finasteride is enough or if dutasteride is needed.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

A 36-year-old shared a 6-month update on their hair transplant of 3,153 grafts, expressing satisfaction with the results and noting improvement in hairline and density. They have been using finasteride and minoxidil for over 13 years, and the feedback was overwhelmingly positive, praising the natural look.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

Exploring a potential hair loss treatment using the enzyme AKR1C2 to locally reduce DHT levels. Challenges include enzyme delivery through the skin and high production costs, with gene therapy or stem cells suggested as future alternatives.

Switching from powdered dutasteride to softgel significantly reduced DHT levels, suggesting softgels are more effective due to better bioavailability. Users discuss the ineffectiveness of compounded forms and emphasize the importance of proper formulation for absorption.

The conversation discusses a hair transplant of 3,200 grafts for Afro hair, 19 days post-operation. Users question the necessity of the number of grafts and inquire about the cost and location of the procedure.

A user shared progress pictures after 5 months of using Dutasteride 0.5 mg and Minoxidil 2.5 mg, with a hair transplant planned for August 2027. Suggestions included increasing Minoxidil dosage and considering Finasteride if results are not satisfactory.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

A person had a hair transplant at Diamond Hair Clinic with Dr. Mehmet Demircioglu using the Sapphire FUE method with 4500 grafts. They are using Duasteride, oral and topical Minoxidil, and vitamins for recovery and hair growth.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.